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Abstract 438 
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular 439 
disease. We report the largest genetic association study of blood pressure traits (systolic, 440 
diastolic, pulse pressure) to date in over one million people of European ancestry. We 441 
identify 535 novel blood pressure loci that not only offer new biological insights into blood 442 
pressure regulation but also reveal shared genetic architecture between blood pressure and 443 
lifestyle exposures. Our findings identify new biological pathways for blood pressure 444 
regulation with potential for improved cardiovascular disease prevention in the future.  445 
  446 
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INTRODUCTION 447 
High blood pressure (BP) is a leading heritable risk factor for stroke and coronary artery 448 
disease, responsible for an estimated 7.8 million deaths and 148 million disability life years 449 
lost worldwide in 2015 alone1. Blood pressure is determined by complex interactions 450 
between life-course exposures and genetic background2-4. Previous genetic association 451 
studies have identified and validated variants at 274 loci with modest effects on population 452 
BP, explaining in aggregate ~3% of the trait variance5-12. 453 
Here, we report genome-wide discovery analyses of BP traits - systolic (SBP), diastolic (DBP) 454 
and pulse pressure (PP) - in people of European ancestry drawn from UK Biobank (UKB)13 455 
and the International Consortium of Blood Pressure-Genome Wide Association Studies 456 
(ICBP)11,12. We adopted a combination of a one- and two-stage study design to test common 457 
and low-frequency single nucleotide polymorphisms (SNPs) with minor allele frequency 458 
(MAF) ≥ 1% associated with BP traits (Fig. 1). In all, we studied over 1 million people of 459 
European descent, including replication data from the US Million Veterans Program (MVP, 460 
N=220,520)14 and the Estonian Genome Centre, University of Tartu (EGCUT, N=28,742) 461 
Biobank15. 462 
UKB is a prospective cohort study of ~500,000 richly phenotyped individuals, including BP 463 
measurements13, with genotyping by customized array and imputation from the Haplotype 464 
Reference Consortium (HRC) panel, yielding ~7 million SNPs (imputation quality score (INFO) 465 
≥ 0.1 and MAF ≥ 1%)16. We performed genome-wide association studies (GWAS) of BP traits 466 
(N=458,577 Europeans) under an additive genetic model17 (Supplementary Table 1a). 467 
Following LD-score regression18, genomic control (GC) was applied to the UKB data prior to 468 
meta-analysis (Online methods). 469 
In addition, we performed GWAS analyses for BP traits in newly extended ICBP GWAS data 470 
comprising 77 independent studies for up to 299,024 Europeans genotyped with various 471 
arrays, and imputed to either the 1,000 Genomes Reference Panel or the HRC platforms 472 
(Supplementary Table 1b). After QC we applied GC at the individual study level and 473 
obtained summary effect sizes for ~7 million  SNPs with INFO ≥ 0.3 and heterogeneity 474 
Cochran’s Q statistic19 filtered at P ≥ 1 × 10-4 (Online Methods).   475 
We then combined the UKB and ICBP GWAS results using inverse-variance weighted fixed 476 
effects meta-analysis (Online Methods), giving a total discovery sample of up to 757,601 477 
individuals20.   478 
In our two-stage design we attempted replication (in MVP and EGCUT, Supplementary 479 
Table 1c) of 1,062 SNPs at P < 1 × 10-6 from discovery with concordant effect direction 480 
between UKB and ICBP, using the sentinel SNP (i.e. SNP with smallest P-value at the locus) 481 
after excluding the HLA region (chr 6:25-34MB) and all SNPs in Linkage Disequilibrium (LD) 482 
(r2 ≥ 0.1) or ±500 Kb from any previously validated BP-associated SNPs at the 274 published 483 
loci. Our replication criteria were genome-wide significance (P < 5 × 10-8) in the combined 484 
meta-analysis, P < 0.01 in the replication data and concordant direction of effect between 485 
discovery and replication.   486 
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We additionally undertook a one-stage design to reduce type II error from the two-stage 487 
analysis. We used P < 5 × 10-9 as threshold from the discovery meta-analysis, i.e. an order of 488 
magnitude more stringent than genome-wide significance21, and required an internal 489 
replication P < 0.01 in each of the UKB and ICBP GWAS analyses, with concordant direction 490 
of effect, to minimize false positive findings.  491 
We carried out conditional analyses using genome-wide complex trait analysis (GCTA)22. We 492 
then explored putative function of BP-associated signals using a range of in silico resources, 493 
and evaluated co-occurrence of BP-associated loci with lifestyle exposures and other 494 
complex traits and diseases. Finally, we developed a genetic risk score (GRS) and assessed 495 
impact of BP-associated variants on BP level, risk of hypertension (HTN), other 496 
cardiovascular diseases and in other ethnicities. 497 
RESULTS 498 
We present a total of 535 novel loci (Fig.2, Supplementary Fig. 1): 325 loci claimed from the 499 
two-stage design (Supplementary Tables 2a-c) and an additional 210 claimed from our one-500 
stage design with internal replication (Supplementary Tables 3a-c). Our two-stage design 501 
uniquely identified 121 variants, while 204 also met the one-stage criteria (Fig. 3a); large 502 
numbers of loci would not have been detected by either the one- or two-stage designs 503 
alone (Fig. 3a). For SBP, the distributions of effect sizes are similar for the one-stage 504 
(median = 0.219 mmHg per allele; Inter-Quartile Range (IQR) = 0.202-0.278) and two-stage 505 
loci (median = 0.224; IQR = 0.195-0.267) (P = 0.447) (Supplementary Fig. 2). Of the 210 loci 506 
found only in the one-stage analysis, 186 are also genome-wide significant (P < 5 × 10-8) in 507 
the combined meta-analysis, with all variants, except one, having concordant direction of 508 
effect between discovery and replication (Supplementary Tables 3a-c); of the remaining 24 509 
SNPs, 10 still have concordant direction of effect.  510 
We find support in our data for all 274 previously published BP loci (Supplementary Fig. 1 & 511 
2 and Supplementary Table 4); >95% of the previously reported SNPs covered within our 512 
data are genome-wide significant. Only 6 available SNPs did not reach Bonferroni-513 
significance, likely because they were originally identified in non-European ancestries (e.g. 514 
rs6749447, rs10474346, rs11564022), or from a gene-age interaction analysis (rs16833934). 515 
In addition, we confirmed a further 92 previously reported, but not replicated, loci  516 
(Supplementary Table 5)9; together with 274 previously reported loci confirmed, and 535 517 
novel loci identified here, there are 901 BP-associated loci in total. 518 
Novel genetic loci for blood pressure 519 
Of the 535 independent novel loci, 363 SNPs were associated with one trait, 160 with two 520 
traits and 12 with all three BP traits (Fig. 3b, Supplementary Fig. 3). Using GCTA we 521 
additionally identified 163, genome-wide significant, independent secondary signals with 522 
MAF ≥ 1% associated with BP (Supplementary Table 6), of which 19 SNPs are in LD (r2 ≥ 0.1) 523 
with previously reported secondary signals. This gives a total of 144 new secondary signals; 524 
hence we now report over 1,000 independent BP signals. 525 
The estimated SNP-wide heritability (h2) of BP traits in our data was 0.213, 0.212 and 0.194 526 
for SBP, DBP and PP respectively, with a gain in percentage of BP variance explained. For 527 
13 
 
example, for SBP, percentage variance explained increased from 2.8 % for the 274 528 
previously published loci to 5.7% for SNPs identified at all 901 loci (Supplementary Table 7).  529 
Functional analyses  530 
Our functional analyses approach is summarised in Supplementary Figure 4. First, for each 531 
of the 901 loci we annotated all SNPs (based on LD r2 ≥ 0.8) to the nearest gene within 5kb 532 
of a SNP, identifying 1333 genes for novel loci and 1272 genes for known loci. Then we 533 
investigated these loci for tissue enrichment, DNase hypersensitivity site enrichment and 534 
pathway analyses. At 66 of the 535 novel loci we identified 97 non-synonymous SNPs, 535 
including 8 predicted to be damaging (Supplementary Table 8). 536 
We used chromatin interaction Hi-C data from endothelial cells (HUVEC)23, neural 537 
progenitor cells (NPC), mesenchymal stem cells (HVMSC) and tissue from the aorta (HAEC) 538 
and adrenal gland24 to identify distal associated genes. There were 498 novel loci that 539 
contained a potential regulatory SNP and in 484 of these we identified long-range 540 
interactions in at least one of the tissues or cell types. We found several potential long-541 
range target genes that do not overlap with the sentinel SNPs in the LD block. For example, 542 
the TGFB2 gene forms a 1.2Mb regulatory loop with SNPs in the SLC30A10 locus, and the 543 
TGFBR1 promoter forms a 100kb loop with the COL15A1 locus (Supplementary Table 8). 544 
Our eQTL analysis identified 60 novel loci with eQTLs in arterial and 20 in adrenal tissue 545 
(Supplementary Table 9), substantially increasing those identified in our previously 546 
published GWAS on ~140K UKB individuals10. An example is SNP rs31120122 which defines 547 
an aortic eQTL affecting expression of the MED8 gene within the SZT2 locus. In combination 548 
with Hi-C interaction data in MSC, this supports a role for MED8 in BP regulation, possibly 549 
mediated through repression of smooth muscle cell differentiation. Hi-C interactions 550 
provide supportive evidence for involvement of a further 36 arterial eGenes (genes whose 551 
expression is affected by the eQTLs) that were distal to their eQTLs (e.g PPHLN1, ERAP2, 552 
FLRT2, ACVR2A, POU4F1). 553 
Using DeepSEA we found 198 SNPs in 121 novel loci with predicted effects on transcription 554 
factor binding or on chromatin marks in tissues relevant for BP biology, such as vascular 555 
tissue, smooth muscle and the kidney (Supplementary Table 8).  556 
We used our genome-wide data at a false discovery rate (FDR) < 1% to robustly assess tissue 557 
enrichment of BP loci using DEPICT and identified enrichment across 50 tissues and cells. 558 
(Supplementary Fig 5a; Supplementary Table 10a). Enrichment was greatest for the 559 
cardiovascular system especially blood vessels (P = 1.5 × 10-11) and the heart (P = 2.7 × 10-5). 560 
Enrichment was high in adrenal tissue (P = 3.7 × 10-4) and, for the first time, we observed 561 
high enrichment in adipose tissues (P = 9.8 × 10-9) corroborated by eQTL enrichment 562 
analysis (P < 0.05) (Supplementary Fig. 6; Supplementary Table 9). Evaluation of enriched 563 
mouse knockout phenotype terms also points to the importance of vascular morphology (P 564 
= 6 × 10-15) and development (P = 2.1 × 10-18) in BP. With addition of our novel BP loci, we 565 
identified new findings from both the gene ontology and protein-protein interaction 566 
subnetwork enrichments, which highlight the TGFβ (P = 2.3 × 10-13) and related SMAD 567 
pathways (P = 7 × 10-15) (Supplementary Table 10b, Supplementary Fig. 5b-d).  568 
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We used FORGE25 to investigate the regulatory regions for cell type specificity from DNase I 569 
hypersensitivity sites, which showed strongest enrichment (P < 0.001) in the vasculature 570 
and highly vascularised tissues, as reported in previous BP genetic studies10 (Supplementary 571 
Fig. 7).  572 
Potential therapeutic targets 573 
Ingenuity pathway analysis and upstream regulator assessment showed enrichment of 574 
canonical pathways implicated in cardiovascular disease including pathways targeted by 575 
antihypertensive drugs (e.g. nitric oxide signalling) and also suggested some potential new 576 
targets, such as relaxin signalling. Notably, upstream regulator analysis identified several BP 577 
therapeutic targets such as angiotensinogen, calcium channels, progesterone, natriuretic 578 
peptide receptor, angiotensin converting enzyme, angiotensin receptors and endothelin 579 
receptors (Supplementary Fig. 8).   580 
We developed a cumulative tally of functional evidence at each variant to assist in 581 
variant/gene prioritisation at each locus and present a summary of the vascular expressed 582 
genes contained within the 535 novel loci, including a review of their potential druggability 583 
(Supplementary Fig. 9). The overlap between BP-associated genes and those associated 584 
with antihypertensive drug targets further demonstrates new genetic support for known 585 
drug mechanisms. For example, we report five novel BP associations with targets of five 586 
antihypertensive drug classes (Supplementary Table 11), including the PKD2L1, SLC12A2, 587 
CACNA1C, CACNB4 and CA7 loci - targeted by potassium-sparing diuretics (amiloride), loop 588 
diuretics (bumetanide and furosemide), dihydropyridine, calcium channel blockers, non-589 
dihydropyridines and thiazide-like diuretics (chlortalidone) respectively. Notably in all but 590 
the last case, functional variants in these genes are the best candidates in each locus.  591 
Concordance of BP variants and lifestyle exposures 592 
We examined association of sentinel SNPs at the 901 BP loci with BP-associated lifestyle 593 
traits14 in UKB using either the Stanford Global Biobank Engine (N=327,302) or Gene ATLAS 594 
(N=408,455). With corrected P < 1 × 10-6, we found genetic associations of BP variants with   595 
daily fruit intake, urinary sodium and creatinine concentration, body mass index (BMI), 596 
weight, waist circumference, and intakes of water, caffeine and tea (P = 1.0 × 10-7 to P = 1.3 597 
× 10-46). Specifically, SNP rs13107325 in SLC39A8 is a novel locus for frequency of drinking 598 
alcohol (P = 3.5 × 10-15) and time spent watching TV (P = 2.3 × 10-11) as well as being 599 
associated with BMI (P = 1.6 × 10-33), weight (P = 8.8 × 10-16) and waist circumference (P = 600 
4.7 × 10-11) (Supplementary Table 12). We used unsupervised hierarchical clustering for the 601 
36 BP loci that showed at least one association at P < 1 × 10-6 with the lifestyle-related traits 602 
in UKB (Fig. 4). The heatmap summarises the locus-specific associations across traits and 603 
highlights heterogeneous effects with anthropometric traits across the loci examined. For 604 
example, it shows clusters of associations between BP-raising alleles and either increased or 605 
decreased adult height and weight. We note that some observed cross-trait associations are 606 
in counter-directions to those expected epidemiologically. 607 
Association lookups with other traits and diseases 608 
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We further evaluated cross-trait and disease associations using GWAS catalog26, 609 
PhenoScanner27 and DisGeNET28,29. The GWAS catalog and PhenoScanner search of 610 
published GWAS showed that 77 of our 535 novel loci (using sentinel SNPs or proxies; r2 ≥ 611 
0.8) are also significantly associated with other traits and diseases (Fig. 5, Supplementary 612 
Table 13). We identified APOE as a highly cross-related BP locus showing associations with 613 
lipid levels, cardiovascular-related outcomes and Alzheimer’s disease, highlighting a 614 
common link between cardiovascular risk and cognitive decline (Fig. 5). Other loci overlap 615 
with anthropometric traits, including BMI, birth weight and height (Fig. 5) and with 616 
DisGeNET terms related to lipid measurements, cardiovascular outcomes and obesity (Fig. 617 
6).  618 
We did lookups of our sentinel SNPs in 1H NMR lipidomics data on plasma (N=2,022) and 619 
data from the Metabolon platform (N=1,941) in the Airwave Study30, and used 620 
PhenoScanner to test SNPs against published significant (P < 5 × 10-8) genome vs 621 
metabolome-wide associations in plasma and urine (Online Methods). Ten BP SNPs show 622 
association with lipid particle metabolites and a further 31 SNPs (8 also on PhenoScanner) 623 
show association with metabolites on the Metabolon platform, highlighting lipid pathways, 624 
amino acids (glycine, serine, glutamine), tri-carboxylic acid cycle intermediates 625 
(succinylcarnitine) and drug metabolites (Supplementary Tables 14 and 15). These findings 626 
suggest a close metabolic coupling of BP regulation with lipid and energy metabolism.  627 
Genetic risk of increased blood pressure, hypertension and cardiovascular disease 628 
A weighted GRS for BP levels across all 901 loci was associated with a 10.4 mmHg higher, 629 
sex-adjusted mean SBP in UK Biobank comparing the upper and lower quintiles of the GRS 630 
distribution (95% CI: 10.2 to 10.6 mm Hg, P < 1 × 10-300) and with 12.9 mmHg difference in 631 
SBP (95% CI: 12.6 to 13.1, P < 1 × 10-300) comparing the upper and lower deciles (Fig. 7a, 632 
Supplementary Table 16). In addition, we observed over three-fold sex-adjusted higher risk 633 
of hypertension (OR 3.34; 95% CI: 3.24 to 3.45; P < 1 × 10-300) between the upper and lower 634 
deciles of the GRS in UK Biobank (Fig. 7a). Sensitivity analyses in the independent Airwave 635 
cohort gave similar results (Supplementary Table 17).  636 
We also show that the GRS is associated with increased, sex-adjusted risk of incident stroke, 637 
myocardial infarction and all incident cardiovascular outcomes, comparing upper and lower 638 
deciles of the GRS distribution, with odds ratios of 1.47 (95% CI: 1.35 to 1.59, P = 1.1 × 10-20), 639 
1.50 (95% CI: 1.28 to 1.76, P = 8.0 × 10-7) and 1.52 (95% CI: 1.26 to 1.82, P = 7.7 × 10-6) 640 
respectively (Fig. 7b, Supplementary Table 16). 641 
Extending analyses to other ancestries 642 
We examined associations with BP of both individual SNPs and the GRS among unrelated 643 
individuals of African and South Asian descent in UKB, for the 901 known and novel loci. 644 
Compared to Europeans, 62.4%, 62.5% and 64.8% of the variants among Africans (N=7,782), 645 
and 74.2%, 72.3% and 75% South Asians (N=10,323) have concordant direction of effect for 646 
SBP, DBP and PP respectively (Supplementary Table 18; Supplementary Fig. 10). Pearson 647 
correlation coefficients with effect estimates in Europeans were r2= 0.37 and 0.78 for 648 
Africans and South Asians respectively (Supplementary Fig. 11). We then applied the 649 
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European-derived GRS findings to unrelated Africans (N=6,970) and South Asians (N=8,827). 650 
BP variants in combination were associated with 6.1 mmHg (95% CI: 4.5 to 7.7; P = 4.9 × 10-651 
14) and 7.4 mmHg (95% CI: 6.0 to 8.7; P = 1.7 × 10-26) higher, sex-adjusted mean systolic 652 
pressure among Africans and South Asians, respectively, comparing upper and lower 653 
quintiles of the GRS distribution (Supplementary Tables 19a and 19b). 654 
DISCUSSION  655 
Our study of over 1 million people offers an important step forward in understanding the 656 
genetic architecture of BP. We identified over 1,000 independent signals at 901 loci for BP 657 
traits, and the 535 novel loci more than triples the number of BP loci and doubles the 658 
percentage variance explained, illustrating the benefits of large-scale biobanks. By 659 
explaining 27% of the estimated heritability for BP, we make major inroads into the missing 660 
heritability influencing BP level in the population31. The novel loci open the vista of entirely 661 
new biology and highlight gene regions in systems not previously implicated in BP 662 
regulation. This is particularly timely as global prevalence of people with SBP over 110-115 663 
mm Hg, above which cardiovascular risk increases in a continuous graded manner, now 664 
exceeds 3.5 billion, of whom over 1 billion are within the treatment range 32,33. 665 
Our functional analysis highlights the role of the vasculature and associated pathways in the 666 
genetics underpinning BP traits. We show a role for several loci in the transforming growth 667 
factor beta (TGFβ) pathway including SMAD family genes and the TGFβ gene locus itself. 668 
This pathway affects sodium handling in the kidney, ventricular remodelling, while plasma 669 
levels of TGFβ have recently been correlated with hypertension (Fig. 8)34,35. The activin A 670 
receptor type 1C (ACVR1C) gene mediates the effects of the TGFβ family of signalling 671 
molecules.  A BP locus contains the Bone Morphogenetic Protein 2 (BMP2) gene in the TGFβ 672 
pathway, which prevents growth suppression in pulmonary arterial smooth muscle cells and 673 
is associated with pulmonary hypertension36. Another BP locus includes the Kruppel-like 674 
family 14 (KLF14) gene of transcription factors, induced by low levels of TGFβ receptor II 675 
gene expression, and which has also been associated with type 2 diabetes, 676 
hypercholesterolaemia and atherosclerosis37. 677 
Our analysis shows enrichment of BP gene expression in the adrenal tissue. Autonomous 678 
aldosterone production by the adrenal glands is thought to be responsible for 5-10% of all 679 
hypertension, rising to ~20% amongst people with resistant hypertension38. Some of our 680 
novel loci are linked functionally to aldosterone secretion39,40. For example, the CTNNB1 681 
locus encodes β-catenin, the central molecule in the canonical Wnt signalling system, 682 
required for normal adrenocortical development41,42. Somatic adrenal mutations of this 683 
gene that prevent serine/threonine phosphorylation lead to hypertension through 684 
generation of aldosterone-producing adenomas43,44. 685 
Our novel loci also include genes involved in vascular remodelling, such as vascular 686 
endothelial growth factor A (VEGFA), the gene product of which induces proliferation, 687 
migration of vascular endothelial cells and stimulates angiogenesis. Disruption of this gene 688 
in mice resulted in abnormal embryonic blood vessel formation, while allelic variants of this 689 
gene have been associated with microvascular complications of diabetes, atherosclerosis 690 
and the antihypertensive response to enalapril45. We previously reported a fibroblast 691 
17 
 
growth factor (FGF5) gene locus in association with BP10. Here, we additionally identify a 692 
new BP locus encoding FGF9, which is linked to enhanced angiogenesis and vascular smooth 693 
muscle cell differentiation by regulating VEGFA expression.  694 
Several of our novel loci contain lipid-related genes consistent with the observed strong 695 
associations among multiple cardio-metabolic traits.  For example, the apolipoprotein E 696 
gene (APOE) encodes the major apoprotein of the chylomicron. Recently, APOE serum levels 697 
have been correlated with SBP in population-based studies and in murine knockout models; 698 
disruption of this gene led to atherosclerosis and hypertension46,47. A second novel BP locus 699 
contains the low-density lipoprotein receptor-related protein 4 (LRP4) gene which may be a 700 
target for APOE and is strongly expressed in the heart in mice and humans. In addition, we 701 
identified a novel locus including the apolipoprotein L domain containing 1 gene (APOLD1) 702 
that is highly expressed in the endothelium of developing tissues (particularly heart) during 703 
angiogenesis. 704 
Many of our novel BP loci encode proteins which may modulate vascular tone or signalling. 705 
For example, the locus containing urotensin-2 receptor (UTS2R) gene encodes a class A 706 
rhodopsin family G-protein coupled-receptor that upon activation by the neuropeptide 707 
urotensin II, produces profound vasoconstriction. One novel locus for SBP contains the 708 
relaxin gene, encoding a G-protein coupled receptor, with roles in vasorelaxation and 709 
cardiac function; it signals by phosphatidylinositol 3-kinase (PI3K)48,49, an enzyme which 710 
inhibits vascular smooth muscle cell proliferation and neo-intimal formation50. We identify 711 
the PI3K gene here as a novel BP locus. We also identify the novel RAMP2 locus which 712 
encodes an adrenomedullin receptor51; we previously identified the adrenomedullin (ADM) 713 
gene as a BP locus12. Adrenomedullin is known to exert differential effects on BP in the brain 714 
(vasopressor) and the vasculature (vasodilator). In addition, a locus containing Rho guanine 715 
nucleotide exchange factor 25 (ARHGEF25) gene generates a factor that interacts with Rho 716 
GTPases involved in contraction of vascular smooth muscle and regulation of responses to 717 
angiotensin II52.  718 
We evaluated the 901 BP loci for extant or potentially druggable targets. Loci encoding 719 
MARK3, PDGFC, TRHR, ADORA1, GABRA2, VEGFA and PDE3A are within systems with 720 
existing drugs not currently linked to a known antihypertensive mechanism; they may offer 721 
repurposing opportunities e.g. detection of SLC5A1 as the strongest repurposing candidate 722 
in a new BP locus targeted by the type-2 diabetes drug canagliflozin. This is important as 723 
between 8-12% of patients with hypertension exhibit resistance or intolerance to current 724 
therapies and repositioning of a therapy with a known safety profile may reduce 725 
development costs. 726 
This study strengthens our previously reported GRS analysis indicating that all BP elevating 727 
alleles combined could increase systolic BP by 10 mm Hg or more across quintiles or deciles 728 
of the population distribution, substantially increasing risk of cardiovascular events10. We 729 
previously suggested that genotyping BP elevating variants in the young may lead to 730 
targeted lifestyle intervention in early life that might attenuate the BP rise at older ages10. 731 
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We identified several BP-associated loci that are also associated with lifestyle traits, 732 
suggesting shared genetic architecture between BP and lifestyle exposures 53. We adjusted 733 
our BP GWAS analyses for BMI to control for possible confounding effects, though we 734 
acknowledge the potential for collider bias54. Nonetheless, our findings of possible genetic 735 
overlap between loci associated with BP and lifestyle exposures could support renewed 736 
focus on altering specific lifestyle measures known to affect BP55. 737 
Despite smaller sample sizes, we observed high concordance with direction of effects on BP 738 
traits of BP variants in Africans (> 62%) and South Asians (> 72%). The GRS analyses show 739 
that, in combination, BP variants identified in European analyses are associated with BP in 740 
non-European ancestries, though effect sizes were 30-40% smaller. 741 
Our use of a two- and one-stage GWAS design illustrates the value of this approach to 742 
minimize the effects of stochastic variation and heterogeneity. The one-stage approach 743 
included signals that had independent and concordant support (P < 0.01) from both UKB 744 
and ICBP, reducing the impact of winners’ curse on our findings. Indeed, all but two of the 745 
210 SNPs discovered in the one-stage analysis reach P < 5 × 10-6 in either UKB or ICBP. To 746 
further minimize the risk of reporting false positive loci within our one-stage design, we set 747 
a stringent overall discovery meta-analysis P-value threshold of P < 5 × 10-9, an order of 748 
magnitude smaller than a genome-wide significance P-value, in line with thresholds 749 
recommended for whole genome sequencing22. We found high concordance in direction of 750 
effects between discovery data in the one-stage approach and the replication resources, 751 
with similar distributions of effect sizes for the two approaches.  We note that 24 of the 752 
one-stage SNPs which reached P < 5 × 10-9 in discovery failed to reach genome-wide 753 
significance (P < 5 × 10-8) in the combined meta-analysis of discovery and replication 754 
resources, and hence may still require further validation in future, larger studies.  755 
The new discoveries reported here more than triple the number of loci for BP to a total of 756 
901 and represent a substantial advance in understanding the genetic architecture of BP. 757 
The identification of many novel genes across the genome, could partly support an 758 
omnigenic model for complex traits where genome-wide association of multiple 759 
interconnected pathways is observed. However, our strong tissue enrichment shows 760 
particular relevance to the biology of BP and cardiovascular disease56, suggesting trait-761 
specificity, which could argue against an omnigenic model. Our confirmation of the impact 762 
of these variants on BP level and cardiovascular events, coupled with identification of 763 
shared risk variants for BP and adverse lifestyle could contribute to an early life precision 764 
medicine strategy for cardiovascular disease prevention. 765 
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 1077 
 Figure Legends 1078 
Figure 1. Study design schematic for discovery and validation of loci. ICBP; International 1079 
Consortium for Blood Pressure; N, sample size; QC, quality control; PCA, principal-component 1080 
analysis; GWAS, Genome-wide Association Study; 1000G 1000 Genomes; HRC, Haplotype Reference 1081 
Panel; BP: blood pressure; SNPs, single nucleotide polymorphisms; BMI, body mass index; LMM; 1082 
linear mixed model; UKB, UK Biobank, MAF, minor allele frequency; HLA, Human Leukocyte Antigen; 1083 
MVP, Million Veterans Program; EGCUT; Estonian Genome Center, University of Tartu; SBP, systolic 1084 
blood pressure; DBP, diastolic blood pressure; PP, pulse pressure. 1085 
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Figure 2. Manhattan plot showing the minimum P-value for the association across all blood 1086 
pressure traits in the discovery stage excluding known and previously reported variants. 1087 
Manhattan plot of the discovery genome-wide association meta-analysis in 757,601 individuals 1088 
excluding variants in 274 known loci. The minimum P-value, computed using inverse variance fixed 1089 
effects meta-analysis, across SBP, DBP and PP is presented. The y axis shows the –log10 P values and 1090 
the x axis shows their chromosomal positions. Horizontal red and blue line represents the thresholds 1091 
of P = 5 x 10-8 for genome-wide significance and P = 1 x 10-6 for selecting SNPs for replication, 1092 
respectively. SNPs in blue are in LD (r2 > 0.8) with the 325 novel variants independently replicated 1093 
from the 2-stage design whereas SNPs in red are in LD (r2 > 0.8) with 210 SNPs identified through the 1094 
1-stage design with internal replication. Any loci in black or grey that exceed the significance 1095 
thresholds were significant in the discovery meta-analysis, but did not meet the criteria of 1096 
replication in the one- or two-stage designs. 1097 
Figure 3: Venn Diagrams of Novel Loci Results (a) “Comparison of 1-stage and 2-stage design 1098 
analysis criteria”: For all 535 novel loci, we compare the results according to the association criteria 1099 
used for the one-stage and the two-stage design. Two-hundred and ten loci exclusively met the one-1100 
stage analysis criteria (P <5x10-9 in the discovery meta-analysis [N=757,601], P < 0.01 in UKB 1101 
[N=458,577], P < 0.01 in ICBP [N=299,024] and concordant direction of effect between UKB and 1102 
ICBP). The P-values for the discovery and the ICBP meta-analyses were calculated using inverse 1103 
variance fixed effects meta-analysis. The P-values in UKB were derived from linear mixed modeling 1104 
using BOLT-LMM. Of the 325 novel replicated loci from the 2-stage analysis (genome-wide 1105 
significance in the combined meta-analysis, P < 0.01 in the replication meta-analysis and concordant 1106 
direction of effect), 204 loci would also have met the one-stage criteria, whereas 121 were only 1107 
identified by the two-stage analysis.   (b) “Overlap of Associations across Blood Pressure Traits”. 1108 
For all 535 novel loci, we show the number of loci associated with each blood pressure trait. We 1109 
present the two-stage loci first, followed by the one-stage loci. SBP: systolic blood pressure; DBP: 1110 
diastolic blood pressure; PP: pulse pressure; UKB: UK Biobank; ICBP: International Consortium of 1111 
Blood Pressure. 1112 
Figure 4. Association of blood pressure loci with lifestyle traits. Plot shows unsupervised 1113 
hierarchical clustering of BP loci based on associations with lifestyle-related factors. For the sentinel 1114 
SNP at each BP locus (x-axis), we calculated the -log10(P)*sign(β) (aligned to BP-raising allele) as 1115 
retrieved from the Gene Atlas catalogue (http://geneatlas.roslin.ed.ac.uk). The P-values in Gene 1116 
Atlas were calculated applying linear mixed models. BP loci and traits were clustered according to 1117 
the Euclidean distance amongst -log10(P)*sign(β). Red squares indicate direct associations with the 1118 
trait of interest and blue squares inverse associations. Only SNPs with at least one association at P 1119 
<10-6 with at least one of the traits examined are annotated in the heat-map. All 901 loci are 1120 
considered, both known and novel: novel loci are printed in bold font. SNPs: Single Nucleotide 1121 
Polymorphisms; BP: Blood Pressure. 1122 
Figure 5. Association of blood pressure loci with other traits. Plot shows results from associations 1123 
with other traits which were extracted from the GWAS catalog and PhenoScanner databases for the 1124 
535 novel sentinel SNPs including proxies in Linkage Disequilibrium (r2 ≥ 0.8) with genome-wide 1125 
significant associations. SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; PP: Pulse 1126 
Pressure; HR: Heart Rate; ECG: Electrocardiographic traits; CAD: Coronary Artery Disease CHD; 1127 
Coronary Heart Disease MI; Myocardial Infraction; T2D: Type II Diabetes. 1128 
Figure 6. Association of blood pressure loci with other traits. Plots (a) and (b) show overlap 1129 
between variants associated to (a) traits and (b) diseases in the manually-curated version of the 1130 
DisGeNET database, and all variants in LD r2>0.8 with the known (red bars) SNPs from the 274 1131 
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published loci, and all (green bars) BP variants from all 901 loci. Numbers on top of the bars denote 1132 
the number of SNPs included in DisGeNET for the specific trait or disease. Traits/diseases with an 1133 
overlap of at least 5 variants in LD with all markers are shown. The Y axis shows the percentage of 1134 
variants associated with the diseases that is covered by the overlap. For the sake of clarity, the 1135 
DisGeNET terms for blood pressure and hypertension are not displayed, whereas the following 1136 
diseases have been combined: coronary artery disease (CAD), coronary heart disease (CHD) and 1137 
myocardial infarction (MI); prostate and breast carcinoma; Crohn's and inflammatory bowel 1138 
diseases. 1139 
Figure 7. Relationship of deciles of the genetic risk score (GRS) based on all 901 loci with blood 1140 
pressure, risk of hypertension and cardiovascular disease in UK Biobank. The plots show sex-1141 
adjusted (a) mean systolic blood pressure (SBP) and odds ratios of hypertension (HTN) (N=364,520) 1142 
and (b) odds ratios of incident cardiovascular disease (CVD), myocardial infarction (MI) and stroke 1143 
(N=392,092), comparing each of the upper nine GRS deciles with the lowest decile; dotted lines 1144 
represent the upper 95% confidence intervals. 1145 
Figure 8: Known and novel BP associations in the TGFβ signalling pathway. Genes with known 1146 
associations with BP are indicated in cyan. Genes with novel associations with BP reported in this 1147 
study are indicated in red. TGFβ pathway was derived from an ingenuity canonical pathway. BP: 1148 
Blood Pressure. 1149 
1150 
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ONLINE METHODS 1151 
UK Biobank (UKB) data 1152 
We performed a Genome Wide Association Study (GWAS) analysis in 458,577 UKB 1153 
participants13 (Supplementary Methods). These consist of 408,951 individuals from UKB 1154 
genotyped at 825,927 variants with a custom Affymetrix UK Biobank Axiom Array chip and 1155 
49,626 individuals genotyped at 807,411 variants with a custom Affymetrix UK BiLEVE 1156 
Axiom Array chip from the UK BiLEVE study57, which is a subset of UKB. SNPs were imputed 1157 
centrally by UKB using a reference panel that merged the UK10K and 1000 Genomes Phase 1158 
3 panel as well as the Haplotype Reference Consortium (HRC) panel58.  For current analysis 1159 
only SNPs imputed from the HRC panel were considered. 1160 
UKB phenotypic data 1161 
Following Quality Control (QC) (Supplementary Methods), we restricted our data to a 1162 
subset of post-QC individuals of European ancestry combining information from self-1163 
reported and genetic data (Supplementary Methods) resulting in a maximum of N=458,577 1164 
individuals (Fig. 1, Supplementary Fig. 12).  1165 
Three BP traits were analysed: systolic (SBP), diastolic (DBP) and pulse pressure (PP) 1166 
(difference between SBP and DBP). We calculated the mean SBP and DBP values from two 1167 
automated (N=418,755) or two manual (N=25,888) BP measurements.  For individuals with 1168 
one manual and one automated BP measurement (N=13,521), we used the mean of these 1169 
two values. For individuals with only one available BP measurement (N=413), we used this 1170 
single value. After calculating BP values, we adjusted for medication use by adding 15 and 1171 
10 mmHg to SBP and DBP, respectively, for individuals reported to be taking BP-lowering 1172 
medication (N=94,289)59. Descriptive summary statistics are shown in Supplementary Table 1173 
1a. 1174 
UKB analysis models 1175 
For the UKB GWAS we performed linear mixed model (LMM) association testing under an 1176 
additive genetic model of the three (untransformed) continuous, medication-adjusted BP 1177 
traits (SBP, DBP, PP) for all measured and imputed genetic variants in dosage format using 1178 
the BOLT-LMM (v2.3) software17. We also calculated the estimated SNP-wide heritability 1179 
(h2) in our data.  Within the association analysis, we adjust for the following covariates: sex, 1180 
age, age2, BMI and a binary indicator variable for UKB vs UK BiLEVE to account for the 1181 
different genotyping chips. The analysis of all HRC-imputed SNPs was restricted to variants 1182 
with MAF ≥ 1% and INFO > 0.1. 1183 
Genomic inflation and confounding 1184 
We applied the univariate LD score regression method (LDSR)18 to test for genomic inflation 1185 
(expected for polygenic traits like BP, with large sample sizes, and especially also from 1186 
analyses of such dense genetic data with many SNPs in high LD)60. LDSR intercepts (and 1187 
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standard errors) were 1.217 (0.018), 1.219 (0.020) and 1.185 (0.017) for SBP, DBP and PP 1188 
respectively, and were used to adjust the UKB GWAS results for genomic inflation, prior to 1189 
the meta-analysis. 1190 
International Consortium for Blood Pressure (ICBP) GWAS 1191 
ICBP GWAS is an international consortium to investigate BP genetics6. We combined 1192 
previously reported post-QC GWAS data from 54 studies (N=150,134)11,12,61, with newly 1193 
available GWAS data from a further 23 independent studies (N=148,890) using a fixed 1194 
effects inverse variance weighted meta-analysis.  The 23 studies providing new data were: 1195 
ASCOT-SC, ASCOT-UK, BRIGHT, Dijon 3C, EPIC-CVD, GAPP, HCS, GS:SFHS, Lifelines, JUPITER, 1196 
PREVEND, TWINSUK, GWAS-Fenland, InterAct-GWAS, OMICS-EPIC, OMICS-Fenland, UKHLS, 1197 
GoDARTS-Illumina and GoDarts-Affymetrix, NEO, MDC, SardiNIA, METSIM.  1198 
All study participants were Europeans and were imputed to either the 1000 Genomes 1199 
Project Phase 1 integrated release v.3 [March 2012] all ancestry reference panel62 or the 1200 
HRC panel16. The final enlarged ICBP GWAS dataset included 77 cohorts (N=299,024).  1201 
Full study names, cohort information and general study methods are included in 1202 
Supplementary Table 1b and in Supplementary Tables 20a-c. GC was applied at study-level. 1203 
The LDSR intercepts (standard error) for the ICBP GWAS meta-analysis were 1.089 (0.012), 1204 
1.086 (0.012) and 1.066 (0.011) for SBP, DBP and PP, respectively. 1205 
Meta-analyses of discovery datasets 1206 
We performed a fixed-effects inverse variance weighted meta-analysis using METAL20,63 to 1207 
obtain summary results from the UKB and ICBP GWAS, for up to N=757,601 participants and 1208 
~7.1 M SNPs with MAF ≥ 1% for variants present in both the UKB data and ICBP meta-1209 
analysis for all three traits. The LDSR intercepts (standard error), in the discovery meta-1210 
analysis of UKB and ICBP were 1.156 (0.020), 1.160 (0.021) and 1.113 (0.018) for SBP, DBP 1211 
and PP respectively. The LDSR intercept (standard error), after the exclusion of all published 1212 
BP variants (see below) in the discovery meta-analysis of UKB and ICBP was 1.090 (0.018), 1213 
1.097 (0.017) and 1.064 (0.015) for SBP, DBP and PP respectively, hence showing little 1214 
inflation in the discovery GWAS after the exclusion of published loci (Supplementary Fig. 1215 
13). No further correction was applied to the discovery meta-analysis of UKB and ICBP 1216 
GWAS. 1217 
Previously reported variants  1218 
We compiled from the peer-reviewed literature all 357 SNPs previously reported to be 1219 
associated with BP at the time that our analysis was completed, that have been identified 1220 
and validated as the sentinel SNP in primary analyses from previous BP genetic association 1221 
studies. These 357 published SNPs correspond to 274 distinct loci, according to locus 1222 
definition of: (i) SNPs within ±500kb distance of each other; (ii) SNPs in Linkage 1223 
Disequilibrium (LD), using a threshold of r2 ≥ 0.1, calculated with PLINK (v2.0). We then 1224 
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augment this list to all SNPs present within our data, which are contained within these 274 1225 
published BP loci, i.e. all SNPs which are located ±500kb from each of the 357 published 1226 
SNPs and/or in LD with any of the 357 previously validated SNPs (r2 ≥ 0.1).  1227 
Identification of novel signals: Two-stage and one-stage study designs 1228 
To identify novel signals of association with BP, two complementary study designs (which 1229 
we term here “two-stage design” and “one-stage design”) were implemented in order to 1230 
maximize the available data and minimize reporting of false positive associations.  1231 
Two-stage design: Overview: 1232 
All of the following criteria had to be satisfied for a signal to be reported as a novel signal of 1233 
association with BP using our two-stage design:  1234 
(i) the sentinel SNP shows significance (P < 1 × 10-6) in the discovery meta-analysis 1235 
of UKB and ICBP, with concordant direction of effect between UKB and ICBP; 1236 
(ii) the sentinel SNP is genome-wide significant (P < 5 × 10-8) in the combined meta-1237 
analysis of discovery and replication (MVP and EGCUT) (replication, described 1238 
below);  1239 
(iii) the sentinel SNP shows support (P < 0.01) in the replication meta-analysis of 1240 
MVP and EGCUT alone (Supplementary Methods);  1241 
(iv) the sentinel SNP has concordant direction of effect between the discovery and 1242 
the replication meta-analyses; 1243 
(v) the sentinel SNP must not be located within any of the 274 previously reported 1244 
loci described above. 1245 
The primary replicated trait was then defined as the BP trait with the most significant 1246 
association from the combined meta-analysis of discovery and replication (in the case 1247 
where a SNP was replicated for more than one BP trait.) 1248 
Two-stage design: Selection of variants from the discovery meta-analysis 1249 
We considered for follow-up SNPs in loci non-overlapping with previously reported loci 1250 
according to both an LD threshold at r2 of 0.1 and a 1Mb interval region, as calculated by 1251 
PLINK64. We obtained a list of such SNPs with P < 1 × 10-6 for any of the three BP traits, 1252 
which also had concordant direction of effect between UKB vs ICBP (Supplementary Table 1253 
21). By ranking the SNPs by significance in order of minimum P-value across all BP traits, we 1254 
performed an iterative algorithm to determine the number of novel signals (Supplementary 1255 
Methods), and identify the sentinel SNP (most significant) per locus. 1256 
Two-stage design: Replication analysis 1257 
We considered SNPs with MAF ≥ 1% for an independent replication in MVP (max 1258 
N=220,520)14 and in EGCUT Biobank (N=28,742)15 (Supplementary Methods). This provides 1259 
a total of N=249,262 independent samples of European descent available for replication. 1260 
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Additional information on the analyses of the two replication datasets is provided in 1261 
Supplementary Methods and in Supplementary Table 1c.  1262 
The two datasets were then combined using fixed effects inverse variance weighted meta-1263 
analysis and summary results for all traits were obtained for the replication meta-analysis 1264 
dataset.  1265 
Two-stage design: Combined meta-analysis of discovery and replication meta-analyses 1266 
The meta-analyses were performed within METAL software63 using fixed effects inverse 1267 
variance weighted meta-analysis (Supplementary Methods). The variants from the 1268 
discovery GWAS that required proxies for replication are shown in Supplementary Table 22. 1269 
The combined meta-analysis of both the discovery data (N=757,601) and replication meta-1270 
analysis (max N=249,262) provided a maximum sample size of N=1,006,863.  1271 
One-stage design: Overview 1272 
Variants that were looked-up but did not replicate according to the two-stage criteria were 1273 
considered in a one-stage design. All of the following criteria had to be satisfied for a signal 1274 
to be reported as a novel signal of association with BP using our one-stage criteria: 1275 
i) the sentinel SNP has P < 5 × 10-9 in the discovery (UKB+ICBP) meta-analysis;  1276 
ii) the sentinel SNP shows support (P < 0.01) in the UKB GWAS alone; 1277 
iii)  the sentinel SNP shows support (P < 0.01) in the ICBP GWAS alone; 1278 
iv) the sentinel SNP has concordant direction of effect between UKB and ICBP 1279 
datasets; 1280 
v) The sentinel SNP must not be located within any of the 274 previously reported 1281 
loci described above (Supplementary Table 4) or the recently reported non-1282 
replicated loci from Hoffman et al9 (Supplementary Table 23).  1283 
We selected the one-stage P-value threshold to be an order of magnitude more stringent 1284 
than a genome-wide significance P-value, so as to ensure robust results and to minimize 1285 
false positive findings. The threshold of P < 5 × 10-9 has been proposed as a more 1286 
conservative statistical significance threshold, e.g. for whole-genome sequencing-based 1287 
studies21. 1288 
Selection of variants from the meta-analysis of UKB and ICBP was performed as described 1289 
above for the two-stage design.  1290 
Conditional Analysis 1291 
We performed conditional analyses using the GWAS discovery meta-analysis data, in order 1292 
to identify any independent secondary signals in addition to the sentinel SNPs at the 901 1293 
loci. We used two different methodological approaches, each using the Genome-wide 1294 
Complex Traits Analysis (GCTA) software22: (i) full “genome-wide conditional analysis” with 1295 
joint multivariate analysis and stepwise model selection across all three BP traits; and (ii) 1296 
“locus-specific conditional analysis” for the primary BP trait conditioning on the sentinel 1297 
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SNPs within each locus (Supplementary Methods). For robustness, secondary signals are 1298 
only reported if obtained from both approaches. All secondary signals were selected at 1299 
genome-wide significance level, with MAF ≥ 1% and confirmed to be pairwise-LD-1300 
independent (r2 < 0.1), as well as not being in LD with any of the published or sentinel SNPs 1301 
at any of the 901 BP-associated loci (r2 < 0.1). In all cases the UKB data was used as the 1302 
reference genetic data for LD calculation, restricted to individuals of European ancestry 1303 
only. 1304 
Functional analyses: Variants 1305 
We used an integrative bioinformatics approach to collate functional annotation at both the 1306 
variant level (for each sentinel SNP within all BP loci) and the gene level (using SNPs in LD r2 1307 
≥ 0.8 with the sentinel SNPs). At the variant level, we use Variant Effect Predictor (VEP) to 1308 
obtain comprehensive characterization of variants, including consequence (e.g. downstream 1309 
or non-coding transcript exon), information on nearest genomic features and, where 1310 
applicable, amino acid substitution functional impact, based on SIFT and PolyPhen. The 1311 
biomaRt R package is used to further annotate the nearest genes. 1312 
We evaluated all SNPs in LD (r2 ≥ 0.8) with our novel sentinel SNPs for evidence of mediation 1313 
of expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue 1314 
Expression (GTEx) database, to highlight specific tissue types which show eQTLs for a larger 1315 
than expected proportion of novel loci. We further seek to identify novel loci with the 1316 
strongest evidence of eQTL associations in arterial tissue, in particular. A locus is annotated 1317 
with a given eGene only if the most significant eQTL SNP for the given eGene is in high LD (r2 1318 
≥ 0.8) with the sentinel SNP, suggesting that the eQTL signal co-localises with the sentinel 1319 
SNP. 1320 
We annotated nearest genes, eGenes (genes whose expression is affected by eQTLs) and Hi-1321 
C interactors with HUVEC, HVMSC and HAEC expression from the Fantom5 project. Genes 1322 
that had higher than median expression levels in the given cell types were indicated as 1323 
expressed. 1324 
To identify SNPs in the novel loci that have a non-coding functional effect (influence binding 1325 
of transcription factors or RNA polymerase, or influence DNase hypersensitivity sites or 1326 
histone modifications), we used DeepSEA, a deep learning algorithm, that learnt the binding 1327 
and modification patterns of ~900 cell/factor combinations65. A change of >0.1 in the 1328 
binding score predicted by DeepSEA for the reference and alternative alleles respectively 1329 
was used as cut-off to find alleles with non-coding functional effect (Supplementary 1330 
Methods) 1331 
We identified potential target genes of regulatory SNPs using long-range chromatin 1332 
interaction (Hi-C) data from HUVECs23, aorta, adrenal glands, neural progenitor and 1333 
mesenchymal stem cell, which are tissues and cell types that are considered relevant for 1334 
regulating BP24. We find the most significant promoter interactions for all potential 1335 
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regulatory SNPs (RegulomeDB score ≤ 5) in LD (r2 ≥ 0.8) with our novel sentinel SNPs and 1336 
published SNPs, and choose the interactors with the SNPs of highest regulatory potential to 1337 
annotate the loci. 1338 
We then performed overall enrichment testing across all loci. Firstly, we used DEPICT66 1339 
(Data-driven Expression Prioritized Integration for Complex Traits) to identify tissues and 1340 
cells which are highly expressed at genes within the BP loci (Supplementary Methods). 1341 
Secondly, we used DEPICT to test for enrichment in gene sets associated with biological 1342 
annotations (manually curated and molecular pathways, phenotype data from mouse KO 1343 
studies) (Supplementary Methods). We report significant enrichments with a false 1344 
discovery rate <0.01. The variants tested were i) the 357 published BP associated SNPs at 1345 
the time of analysis and ii) a set including all (published and novel) variants (with novel SNPs 1346 
filtered by highest significance, P < 1 × 10-12). 1347 
Furthermore, to investigate cell type specific enrichment within DNase I sites, we used 1348 
FORGE, which tests for enrichment of SNPs within DNase I sites in 123 cell types from the 1349 
Epigenomics Roadmap Project and ENCODE25 (Supplementary Methods). Two analyses 1350 
were compared (i) using published SNPs only; (ii) using sentinel SNPs at all 901 loci, in order 1351 
to evaluate the overall tissue specific enrichment of BP associated variants. 1352 
Functional analyses: Genes 1353 
At the gene level, we used Ingenuity Pathway Analysis (IPA) software (IPA®, QIAGEN 1354 
Redwood City) to review genes with prior links to BP, based on annotation with the 1355 
“Disorder of Blood Pressure”, “Endothelial Development” and “Vascular Disease” Medline 1356 
Subject Heading (MESH) terms. We used the Mouse Genome Informatics (MGI) tool to 1357 
identify BP and cardiovascular relevant mouse knockout phenotypes for all genes linked to 1358 
BP in our study. We also used IPA to identify genes that interact with known targets of anti-1359 
hypertensive drugs. Genes were also evaluated for evidence of small molecule druggability 1360 
or known drugs based on queries of the Drug Gene Interaction database. 1361 
Lookups in non-European ancestries 1362 
As a secondary analysis, we look up all known and novel BP-associated SNPs in Africans 1363 
(7,782) and South Asians (10,322) from UKB using BOLT-LMM analysis for each BP trait 1364 
within each ancestry (Supplementary Methods). 1365 
Effects on other traits and diseases 1366 
We queried SNPs against GWAS catalog26 and PhenoScanner27, including genetics and 1367 
metabolomics databases, to investigate cross-trait effects, extracting all association results 1368 
with genome-wide significance at P < 5 × 10-8 for all SNPs in high LD (r2 ≥ 0.8) with the 535 1369 
sentinel novel SNPs, to highlight the loci with strongest evidence of association with other 1370 
traits. We further evaluated these effects using DisGeNET28,29. At the gene level, 1371 
overrepresentation enrichment analysis (ORA) with WebGestalt67 on the nearest genes to 1372 
all BP loci was carried out. Moreover, we tested sentinel SNPs at all published and novel 1373 
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(N=901) loci for association with lifestyle related data including food, water and alcohol 1374 
intake, anthropomorphic traits and urinary sodium, potassium and creatinine excretion 1375 
using the recently developed Stanford Global Biobank Engine and the Gene ATLAS68. Both 1376 
are search engines for GWAS findings for multiple phenotypes in UK Biobank. We used a 1377 
Bonferroni corrected significance threshold of P < 1 × 10-6 to deem significance. 1378 
Genetic risk scores and percentage of variance explained  1379 
We calculated a weighted genetic risk score (GRS) (Supplementary Table 24) to provide an 1380 
estimate of the combined effect of the BP raising variants on BP and risk of hypertension 1381 
and applied this to the UKB data (Supplementary Methods). Our analysis included 423,713 1382 
unrelated individuals of European ancestry of whom 392,092 individuals were free of 1383 
cardiovascular events at baseline.  1384 
We assessed the association of the continuous GRS variable on BP and with the risk of 1385 
hypertension, with and without adjustment for sex. We then compared BP levels and risk of 1386 
hypertension, respectively, for individuals in the top vs bottom quintiles of the GRS 1387 
distribution. Similar analyses were performed for the top vs bottom deciles of the GRS 1388 
distribution. All analyses were restricted to the 392,092 unrelated individuals of European 1389 
ancestry from UKB.  As a sensitivity analysis to assess for evidence of bias in the UKB results, 1390 
we also carried out similar analyses in Airwave, an independent cohort of N=14,004 1391 
unrelated participants of European descent30 (Supplementary Methods). 1392 
We calculated the association of the GRS with cardiovascular disease in unrelated 1393 
participants in UKB data, based on self-reported medical history, and linkage to 1394 
hospitalization and mortality data (Supplementary Table 25). We use logistic regression 1395 
with binary outcome variables for composite incident cardiovascular disease 1396 
(Supplementary Methods), incident myocardial infarction and incident stroke (using the 1397 
algorithmic UKB definitions) and GRS as explanatory variable (with and without sex 1398 
adjustment).   1399 
We also assessed the association of this GRS with BP in unrelated individuals Africans 1400 
(N=6,970) and South Asians (N=8,827) from the UKB to see whether BP-associated SNPs 1401 
identified from GWAS predominantly in Europeans are also associated with BP in 1402 
populations of non-European ancestry. 1403 
We calculated the percentage of variance in BP explained by genetic variants using the 1404 
independent Airwave cohort (N=14,004) (Supplementary Methods). We considered three 1405 
different levels of the GRS: (i) all pairwise-independent, LD-filtered (r2 < 0.1) published SNPs 1406 
within the known loci; (ii) all known SNPs and sentinel SNPs at novel loci; (iii) all 1407 
independent signals at all 901 known and novel loci including the 163 secondary SNPs. 1408 
Data availability statement  1409 
The UKB GWAS data can be assessed from the UK Biobank data repository 1410 
(http://biota.osc.ox.ac.uk/). The genetic and phenotypic UKB data are available upon 1411 
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application to the UK Biobank (https://www.ukbiobank.ac.uk). ICBP summary data can be 1412 
assessed through request to ICBP steering committee. Contact Mark Caulfield 1413 
(m.j.caulfield@qmul.ac.uk) or Paul Elliott (p.elliott@imperial.ac.uk) to apply for access to 1414 
the data. The UKB+ICBP summary data can be assessed through request to Paul Elliott 1415 
(p.elliott@imperial.ac.uk) or Mark Caulfield (m.j.caulfield@qmul.ac.uk). All replication data 1416 
generated during this study are included in the published article. For example, association 1417 
results of look-up variants from our replication analyses and the subsequent combined 1418 
meta-analyses are contained within the Supplementary Tables provided. 1419 
Reporting Summary 1420 
Further information on experimental design is available in the Life Sciences Reporting 1421 
Summary linked to this article.  1422 
Ethics Statement 1423 
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is available in Supplementary Methods. 1428 
References 1429 
57. Wain, L.V. et al. Novel insights into the genetics of smoking behaviour, lung function, 1430 
and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study 1431 
in UK Biobank. Lancet Respir Med 3, 769-81 (2015). 1432 
58. Bycroft, C.F., C; Petkova, D; Band, G; Elliot, LT; Sharp, K; Motyer, A; Vukcevic, D; 1433 
Delaneau, O; O'Conell, J; Cortes, A; Welsh, S; McVean, G; Leslie, S; Donelly, P; 1434 
Marchini, J. Genome-wide geentic data on 500,000 UK Biobank Participants. bioRxiv 1435 
166298 (2017). 1436 
59. Tobin, M.D., Sheehan, N.A., Scurrah, K.J. & Burton, P.R. Adjusting for treatment 1437 
effects in studies of quantitative traits: antihypertensive therapy and systolic blood 1438 
pressure. Stat Med 24, 2911-35 (2005). 1439 
60. Marouli, E. et al. Rare and low-frequency coding variants alter human adult height. 1440 
Nature 542, 186-190 (2017). 1441 
61. Wain, L.V. et al. Genome-wide association study identifies six new loci influencing 1442 
pulse pressure and mean arterial pressure. Nat Genet 43, 1005-11 (2011). 1443 
62. 1000 Genomes Project Consortium et al. A global reference for human genetic 1444 
variation. Nature 526, 68-74 (2015). 1445 
63. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of 1446 
genomewide association scans. Bioinformatics 26, 2190-1 (2010). 1447 
64. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-1448 
based linkage analyses. Am J Hum Genet 81, 559-75 (2007). 1449 
65. Zhou, J. & Troyanskaya, O.G. Predicting effects of noncoding variants with deep 1450 
learning-based sequence model. Nat Methods 12, 931-4 (2015). 1451 
66. Pers, T.H. et al. Biological interpretation of genome-wide association studies using 1452 
predicted gene functions. Nat Commun 6, 5890 (2015). 1453 
36 
 
67. Wang, J., Vasaikar, S., Shi, Z., Greer, M. & Zhang, B. WebGestalt 2017: a more 1454 
comprehensive, powerful, flexible and interactive gene set enrichment analysis 1455 
toolkit. Nucleic Acids Res (2017). 1456 
68. Canela-Xandri, O.R., Konrad; Tenesa, Albert. An atlas of genetic associations in UK 1457 
Biobank. bioRxiv 176834 (2017). 1458 
 1459 
Genetic/phenotypic data QC → N=458,577
Exclude samples with high missingness/heterozygosity, 
sex discordance, QC failures, missing covariates, 
pregnant, retracted informed consent
restrict to Europeans using PCA
Two-stage analysis
Follow-up SNPs with P < 1 × 10-6 for any BP trait
(with concordant direction of effect for UKB vs ICBP)
Independent Replication meta-analysis
→ Lookups of sentinel SNPs 
in MVP (N=220,520) and EGCUT (N=28,742)
→ combined meta-analysis (N=1,006,863)
(i) genome-wide significant (P < 5 × 10-8) in combined meta
(ii) P < 0.01 in replication meta-analysis
(iii) concordant direction of effect
325 novel replicated loci
from two-stage analysis
SBP (130), DBP (91), PP (104)
92 newly replicated loci 
(previously published without 
independent replication)
535 novel  loci
D
at
a
Q
C
D
is
co
ve
ry
 
R
ep
lic
at
io
n
Va
lid
at
io
n
Genetic/phenotypic data QC → N=299,024
150,134 previously published (54 cohorts), centrally QC-ed
Plus 148,890 samples from 23 newly QC-ed cohorts. 
Including study-level GC-adjustment
European samples only
ICBP data
N=299,024 from 77 different cohorts
UK Biobank data
N=502,620 with genetic & phenotypic data
One-stage analysis
Consider any novel sentinel lookup SNPs which do 
not replicate from 2-stage analysis
→ UKB-ICBP Internal Replication
(i) P < 5 × 10-9 from UKB+ICBP discovery meta
(ii) P < 0.01 in UKB GWAS
(iii) P < 0.01 in ICBP GWAS meta-analysis
(iv) concordant direction of effect UKB vs ICBP
210 novel loci from one-stage analysis
(internally replicated)
SBP (60), DBP (103), PP (47)
Exclude all SNPs in 274 known BP loci, using SNPs previously reported at time of analysis
Locus Definition: (r2 ≥ 0.1; 1Mb region ±500kb from sentinel SNP)
(also fully exclude HLA region: chr6:25-34 Mb)
ICBP-Plus meta-analysis 
ICBP-GWAS of imputed SNPs (1000G or HRC panels)
Fixed effects inverse variance weighted meta-analysis; 
stringent meta-level QC-filtering
UK Biobank GWAS analysis  
UKB GWAS of HRC imputed SNPs
BP ~ SNP + sex + age + age2 + BMI + array
using BOLT-LMM 
→ LD Score Regression → GC-adjustment
UKB+ICBP- GWAS Discovery meta-analysis (N=757,601)

(A) (B)
SBP
DBP
PP
65	/	32
64	/	88
73	/	41
53	/	 28
57	/	17
58	/	4
210 204 121

Anthropometric
Autoimmune Cancer
Eye
HR/ECG/CAD
/CHD/MI Kidney / 
Thyroid
Lifestyle
Lipids
Neuro
T2D/Metabolic
Other
Haematological
Thrombosis / 
Coagulation
SBP
PP
DBP
0
2
4
6
8
10
12
14
16
Se
ru
m
 to
ta
l c
ho
les
te
ro
l
Tr
igl
yc
er
ide
s
Lo
w 
de
ns
ity
 lip
op
ro
te
in 
ch
ole
ste
ro
l
Ur
ic 
ac
id 
(p
ro
ce
du
re
)
He
m
og
lob
in
Hi
gh
 d
en
sit
y l
ipo
pr
ot
ein
Fi
br
ino
ge
n 
as
sa
y
Fa
sti
ng
 b
loo
d 
glu
co
se
Cr
ea
tin
ine
, s
er
um
 (p
ro
ce
du
re
)
Gl
om
er
ula
r f
iltr
at
ion
 ra
te
 fin
din
g
M
ea
n 
Co
rp
us
cu
lar
 V
olu
m
e
El
ec
tro
ca
rd
iog
ra
m
: P
−R
 in
te
rv
al
Ad
ipo
ne
cti
n
Al
ka
lin
e 
ph
os
ph
at
as
e
Pe
rc
en
t o
ve
rla
p
Known loci
All loci
ba
0
2
4
6
8
10
12
Cr
oh
n's
 a
nd
 IB
D
Pr
os
ta
te
 a
nd
 B
re
as
t c
ar
cin
om
a
Ul
ce
ra
tiv
e 
Co
liti
s
Sc
hiz
op
hr
en
ia
Lu
pu
s E
ry
th
em
at
os
us
, S
ys
te
m
ic
CA
D,
 C
HD
 a
nd
 M
I
Ch
ro
nic
 K
idn
ey
 D
ise
as
es
Ob
es
ity
Di
ab
et
es
 M
ell
itu
s, 
No
n−
In
su
lin
−D
ep
.
Pe
rc
en
t o
ve
rla
p
Known loci
All loci
N=168
N=226
N=190
N=221
N=50
N=249
N=86
N=91
N=101
N=114
N=189
N=146
N=65
N=30
N=705
N=553 N=274
N=948
N=336
N=274
N=111
N=181
N=342
l i
ll l i
Known loci
All loci
a	 b	
Deciles GRS
SB
P 
(m
m
Hg
)
13
4
13
6
13
8
14
0
14
2
14
4
14
6
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
●
●
●
●
●
●
●
●
●
●
1
1.
5
2
2.
5
3
3.
5
Od
ds
 R
at
io 
HT
N
● Hypertension
SBP
●
●
●
●
●
●
●
● ●
●
●
●
1 2 3 4 5 6 7 8 9 10
Deciles GRS
0.
9
1
1.
1
1.
2
1.
3
1.
4
1.
5
1.
6
1.
7
Od
ds
 R
at
io 
(9
5%
 C
I)
● Incident CVD 
Incident MI 
Incident Stroke

